Antibiotics can sometimes be almost miraculous in their clinical impact. Over the last 70 years, since their introduction into routine medical practice, they’ve saved countless lives.
But in many cases the benefits are much less dramatic or apparent. Further, there is increasing evidence that routine use of antibiotics can have long-term detrimental effects on human health, owing to their actions on the gut microbiome.
Epidemiologic data and experimental models both link antibiotic exposure to metabolic and immunological changes, which are important driving factors in common diseases including obesity, diabetes, and asthma. This is an important clinical issue, one that calls out for effective solutions.
In this webinar, you’ll have an opportunity to learn from Martin Blaser, MD, one of the world’s leading microbiologists and experts on the impact of antibiotics on the microbiome. Dr. Blaser and his team at Rutgers University have been at the forefront of research on microbiome changes and the role of these changes in fueling the epidemics of metabolic and inflammatory diseases such as asthma, obesity, diabetes, IBD, and others.
Dr. Blaser explores:
- The effects of antibiotic exposure on microbiome development in early life
- The associations between antibiotic use and common illnesses
- The evidence from animal models that antibiotic exposure is a causal factor in changing physiology and promoting disease development
- Future approaches to solving this significant clinical problem
Sponsored by HOWARU Probiotics. HOWARU® premium probiotic strains power probiotic brands that are focused on efficacy and quality. With more than 100 years of probiotic development and manufacturing experience, our scientists have studied thousands of strains, and selected strains with clinically demonstrated benefits to be designated as HOWARU®.
HOWARU® Single strains and pre-formulated blends have been studied under Good Clinical Practice guidelines to ensure the highest scientific and ethical standards and appear in leading peer-reviewed publications and evidence-based guidelines. When you recommend probiotics check to see if the brand you are recommending contains HOWARU® probiotic strains. Feel free to check out the website https://www.howaru.com/hcp/ to learn more about HOWARU® strain clinical data and commitment to quality. Check in periodically to review the latest scientific information on probiotics from the world leading manufacturers of probiotic strains.
Martin J. Blaser, MD, holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University, and serves as Director of the Center for Advanced Biotechnology and Medicine. Previously, he served as Chair of the Department of Medicine at New York University. A physician and microbiologist, Dr. Blaser’s main area of interest is in the relationships we have with the microbiome, with particular focus on how these relationships influence human health and illness. His research explores the role of microbiome changes in the etiology of diseases that are currently epidemic, including obesity, diabetes, asthma, and allergic/auto-immune disorders. Dr. Blaser has served as President of the Infectious Diseases Society of America, Chair of the Board of Scientific Counselors of the National Cancer Institute, and Chair of the Advisory Board for Clinical Research of the NIH. He is currently Chair of the Presidential Advisory Council for Combatting Antibiotic Resistant Bacteria (PACCARB). He has authored over 600 original scientific articles, and holds 24 US patents. His landmark 2014 boo, Missing Microbes, has now been translated into 20 languages.